Key Takeaways
- 22% revenue growth, margin jump: Revenue expanded 22% YoY while EBITDA margin reached 22.7%, driven by operating leverage, cost optimization, and lower raw material costs.
- Teva plant nearing revenue inflection: Phase 1 capacity trending toward 360 crore units per annum by March, with management targeting INR600-odd crores in incremental revenue from the facility in FY25.
- Raw material tailwind delivered two-thirds of margin gain: Management sees sustainability as a "huge possibility" but cautioned it is too early to confirm further reductions.
- Freight disruption a manageable headwind: Sea route disruptions doubled freight rates from historic lows, but the impact on margins is expected to be well under 50-100 bps.
- What to watch next quarter: Whether Teva plant revenue begins to flow in Q1 FY25 as guided, the trajectory of raw material costs, and any concrete update on the new acquisition dialogue.
Teva Plant Ramp-Up
- Phase 1 on track: The facility is trending toward a 360 crore tablet per annum run rate by March, which will be an all-time high for the plant under Marksans ownership but below Teva's historical peak.
- Phase 2 timeline: Targeting over 600 crore tablets per annum, anticipated toward the middle or end of the next financial year.
- Revenue contribution in FY25: Management is aiming for INR600-odd crores in additional revenue from the facility next year, with contracts already signed assuming the capacity ramp-up materializes.
- Operating leverage yet to kick in: The plant has not yet broken even; depreciation has already stepped up to an INR22 crore base, so margin expansion from operating leverage will begin once revenue starts in the next financial year.
- Teva contract ending: The legacy contract with Teva expires in April 2024, and management is not inclined to accept an extension because the company has its own objectives to achieve with the asset.
Mark Saldanha: "we are aiming for INR600-odd crores next year, in next financial year. So, we have two phases that we are, like I mentioned, we are talking of, I think in March we'll be hitting an all-time high, but that's not a great achievement compared to what historically Teva was doing."
Margin Drivers & Sustainability
- Raw material the dominant contributor: Approximately two-thirds of the EBITDA improvement came from the raw material side, with a reduction in a few key input prices continuing versus last year.
- Gross margin sustainability: Management believes the elevated gross margin level is largely sustainable, acknowledging a one-off component but expressing confidence in maintaining the level.
- Freight impact contained: Freight rates have doubled from historic lows due to sea route disruptions but remain below historic highs; the impact on margins is expected to be very less than 50-100 bps, with contracts negotiated during the Nov-Feb window.
- Forex one-off in PAT: A GBP fluctuation from INR101 to INR106 between September and December created a mark-to-market impact; the rate has since stabilized at INR104-105, with no incremental hit expected but a revaluation due on 31st March.
- Further raw material reduction uncertain: Pricing is looking much more stable now, and while management hopes for further reductions, it is too early to call.
Mark Saldanha: "I do believe sustainability is a huge possibility. I do believe there is a one-off, so I do believe we should be able to maintain that gross margin part of it."
Geographic & Segment Performance
| Market | Trend | Commentary |
|---|---|---|
| US | ▲ Strong growth | New product launches, bigger market share, penetrating new retailers; core strength products maturing and growing. |
| UK | ▲ Robust growth | Portfolio product mix and new product launches driving expansion; matured market so new launches achieve penetration faster. Growth expected to remain robust for the next couple of years. |
| Australia | ▼ Muted | Timing of approvals and post-COVID distribution channel flooding; season less inductive compared to historic seasons. Plan to be on track next financial year. |
- US OTC opportunity: The OTC segment is more contract-driven with longer gestation and greater stability than Rx; management sees the market as huge, with the company "just at the top of the iceberg."
- US Rx price erosion: Some price erosion continues on the Rx front due to demand-supply dynamics, but the overall basket has a bit of stability.
- US vs UK margin profile: The UK is a matured market (active since 2008) with operating leverage and market penetration already built in; the US market is relatively new (active since 2017) and has a long way to go on margin expansion.
Mark Saldanha: "The market size is huge, and I think we are just at the top of the iceberg for us."
Product Pipeline & Backward Integration
- Niche, high-value launches: New products span digestive, cold, pain, prescription, and anti-depressant categories; individually they will not drive the top line, but as a basket they will collectively grow revenue with strong bottom-line contribution.
- Complex molecule approvals expected: Filings include dual-action products, extended release, bi-layered, and MOPS technology type molecules; more approvals are expected cumulatively.
- UK filing ambition: Planning 34 new filings in the next two years in the UK market.
- First DMF filed: The company has initiated filing of its first Drug Master File, a step toward backward integration; a second DMF is planned for filing within this quarter.
- EIR report received: The Goa plant received its Establishment Inspection Report and the audit has been closed.
Mark Saldanha: "These products are little niche products, high value products, great bottom lines. They are not, they will not be driving the top line, but as a basket collectively, the top line will basically, will grow."
Capital Allocation & Expansion
- Capex trajectory: By end of March, total capex should cross INR200 crores including Teva acquisition costs; over FY24 and FY25 combined, overall capex will be between INR250 to INR300 crores.
- Geographic expansion: The company is looking at expanding presence geographically and spreading business in the EU, with some amount earmarked for that purpose.
- Acquisition dialogue ongoing: A new acquisition is still in progress and in dialogue, but nothing is concrete and it remains far away; management declined to provide details.
- Free cash flow allocation undecided: Management indicated roughly 25% of free cash flow will be divided between dividends and buybacks, but the exact split (fully dividend, 25% buyback, or 100% dividend) is a call yet to be taken.
- R&D spend: Expected to touch and cross slightly over 2% of sales.
Mark Saldanha: "Right now we have not shown any plans, although they are looking for an extension, but we are not inclined to accept that extension because we have our own objectives to achieve."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | Cross INR3,000 crores | Within the next two years |
| Teva plant Phase 1 capacity | 360 crore tablets per annum run rate | By March |
| Teva plant Phase 2 capacity | Over 600 crore tablets per annum | Middle or end of next financial year |
| Teva plant incremental revenue | INR600-odd crores additional revenue | FY25 |
| Total capex (FY24 + FY25) | INR250 to INR300 crores | Over two years |
| Second DMF filing | File second DMF | Within this quarter |
| UK new filings | 34 new filings | Next two years |
| Effective tax rate | 24% to 25% | Going forward |
| R&D spend | Slightly over 2% of sales | Ongoing |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Operating revenue | ₹586 cr, +22% YoY vs ₹479 cr |
| US & North America revenue | ₹257 cr, +18% YoY |
| UK & EU revenue | ₹251 cr, +34% YoY |
| Australia & New Zealand revenue | ₹48.6 cr |
| Rest of world revenue | ₹29.1 cr |
| Gross margin | 53.5%, +336 bps YoY from 50.1% |
| EBITDA | ₹133 cr, +73.6% YoY and +16.8% QoQ |
| EBITDA margin | 22.7% |
| Profit after tax | ₹83 cr, +33.2% YoY and -1.1% QoQ |
| EPS | ₹1.84 |
| 9M FY24 operating revenue | ₹1,617 cr, +18.4% YoY vs ₹1,366 cr |
| 9M FY24 EBITDA margin | 21.6% |
| 9M FY24 PAT | ₹237.3 cr, +29.9% YoY vs ₹182.6 cr |
| 9M net cash from operations | ₹169 cr |
| 9M capex incurred | ₹160.6 cr |
| 9M R&D spend | ₹29.4 cr, 1.8% of sales |
| Cash balance | ₹688 cr as of Dec 31, 2023, debt-free |
| UK OTC vs Rx split | 60% OTC, 40% Rx |
| US OTC vs Rx split | 75% OTC, 25% Rx |
| Teva plant Phase 1 capacity target | Over 360 cr units per annum, trending towards by March 2024 |
| Teva plant Phase 2 capacity target | Over 600 cr tablets per annum, anticipated middle or end of FY25 |
| Teva plant FY25 revenue target | ~₹600 cr, mainly incremental |
| UK new filings planned | 34 in next two years |
| Depreciation benchmark | ₹22 cr per quarter going forward |
| Effective tax rate guidance | 24%–25% going forward |
| FY24 top line estimate | ₹2,200-odd cr (per an analyst's math) |